Integrated computational and experimental analysis explores FOLH1 expression patterns across cancers and nominates melatonin as a potential modulator in prostate cancer models
PLOS Computational Biology · 22.05.2026 · 22 (5) · e1014315
DOI: 10.1371/journal.pcbi.1014315 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 22.05.2026. Verfasst von Rui Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Technology, Peking University Health Science Center, Beijing, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Melatonin, Antigens, Surface. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Special Fund for Research on National Major Research Instruments of China.
Abstract (Originalsprache)
Background
Growing evidence indicates that Folate Hydrolase 1 (FOLH1, also known as prostate-specific membrane antigen, PSMA) is aberrantly expressed across multiple malignancies, particularly showing significant upregulation in prostate cancer. However, systematic investigations into its pan-cancer expression patterns, immunomodulatory roles, and immune cell infiltration remain limited. The potential role of FOLH1 in prostate cancer is also not fully elucidated.
Methods
We analyzed FOLH1 mRNA expression, prognostic relevance, and immune infiltration across multiple malignancies, with a particular focus on prostate cancer. A machine learning (ML) workflow incorporating a deep learning model was developed to screen the therapeutic potential of drugs targeting FOLH1. The therapeutic potential of these candidates was validated through in vitro cellular assays and nude mouse xenograft models.
Results
FOLH1 expression was significantly altered in 27 cancer types and showed cancer-specific immune correlations. Our AI platform identified melatonin as a computationally predicted FOLH1-interacting candidate. In vitro and in vivo experiments demonstrated that melatonin suppresses FOLH1 expression in a concentration-dependent manner, inhibits invasive and migratory capacities, and restricts tumor growth under physiological circadian melatonin levels.
Conclusion
This study highlights FOLH1’s pan-cancer expression patterns and nominates melatonin as an exploratory therapeutic candidate for prostate cancer requiring further mechanistic validation. Our integrated computational-experimental framework highlights the promise of AI-driven drug discovery in oncology, while emphasizing the need for further mechanistic validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Medical Technology, Peking University Health Science Center, Beijing, China.
- Institute of Advanced Clinical Medicine, Peking University, Beijing, China.
- Department of Biomedical Engineering, Peking University, Beijing, China.
ORCID-Profile: Xunbin Wei
Förderung
- National Key Research and Development Program of China
- Special Fund for Research on National Major Research Instruments of China
Zitieren
APA
Zhang, R., Zhou, J., Dong, S., Liu, G., & Wei, X. (2026). Integrated computational and experimental analysis explores FOLH1 expression patterns across cancers and nominates melatonin as a potential modulator in prostate cancer models. PLOS Computational Biology, 22(5), e1014315. https://doi.org/10.1371/journal.pcbi.1014315
Vancouver
Zhang R, Zhou J, Dong S, Liu G, Wei X. Integrated computational and experimental analysis explores FOLH1 expression patterns across cancers and nominates melatonin as a potential modulator in prostate cancer models. PLOS Computational Biology. 2026;22(5):e1014315. doi:10.1371/journal.pcbi.1014315
BibTeX
@article{Zhang2026,
author = {Zhang, Rui and Zhou, Junyu and Dong, Sihan and Liu, Guoquan and Wei, Xunbin},
title = {Integrated computational and experimental analysis explores FOLH1 expression patterns across cancers and nominates melatonin as a potential modulator in prostate cancer models},
journal = {PLOS Computational Biology},
year = {2026},
volume = {22},
number = {5},
pages = {e1014315},
doi = {10.1371/journal.pcbi.1014315}
}
EUVIMED